Actively Recruiting
CGRP Inhibition, Autonomic Function, and Migraine
Led by Medical University of Vienna · Updated on 2024-12-10
120
Participants Needed
1
Research Sites
321 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine. In addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.
CONDITIONS
Official Title
CGRP Inhibition, Autonomic Function, and Migraine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of chronic migraine according to ICHD-3 criteria
- Diagnosis of episodic migraine with or without aura according to ICHD-3 criteria
- Unsuccessful treatment with three or more established migraine preventive drugs
- Medicine costs are covered by health insurance
- Healthy controls must have no diagnosed chronic disease or acute infection requiring medication
You will not qualify if you...
- Pregnancy or breastfeeding
- Neurosurgical interventions within the last 12 months
- Coronary bypass surgery or other revascularization procedures within the last 12 months
- History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction, or uncontrolled hypertension
- Known allergy to anti-CGRP antibody therapy
- History of disorders (other than migraine) that may affect autonomic test results
- Healthy controls must have no personal or family history of migraine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University of Vienna
Vienna, Austria, 1090
Actively Recruiting
Research Team
A
Antun R Pavelic, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here